CEO Christopher Viehbacher has said consistently since he took the helm of Biogen in 2022 that the company will grow through both internal and external innovation, with an overarching goal of diversifying beyond neurology further into rare diseases and immunology. The hiring of Jane Grogan as head of research a year later reinforced that strategy and the new member of the leadership team told Scrip that she spent 2024 reorganizing her group with those overarching goals in mind.
How Research Head Jane Grogan Is Reinforcing Biogen’s Internal And External R&D Focus
Immunology Interests Fall Into Three ‘Buckets’
CEO Christopher Viehbacher has said repeatedly that Biogen will build its pipeline internally and through deals, and Grogan reshuffled the research organization with that in mind.
More from Strategy
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
Stock prices plummeted, particularly for vaccine makers and cell and gene therapy developers, after the US FDA’s top biologics overseer resigned over vaccine misinformation concerns.
More from Leadership
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.